Skip to main content

Advertisement

Table 1 Clinical characteristics of patients with hip osteoarthritis at baseline

From: Predictors of response to viscosupplementation in patients with hip osteoarthritis: results of a prospective, observational, multicentre, open-label, pilot study

  ITT population N = 97 PP population N = 90 X-Rays population N = 80 P value
Gender (Females) 58.8% 56.7% 53.2% >0.05
Age (Years) 63.0 (36.0–87.0) 63.0 (36.0–87.0) 62.0 (36.0–87.0) >0.05
BMI (kg/m2) 25.1 (17.8–41.8) 24.9 (17.8–41.8) 24.9 (17.8–41.8) >0.05
Disease duration (months) 12.0 (1.0–200.0) 12.0 (1.0–200.0) 12.0 (1.0–200.0) >0.05
WOMAC pain 26.0 (7.0–42.0) 25.0 (7.0–42.0) 26.0 (7.0–42.0) >0.05
WOMAC total 120.0 (41.0–194.0) 116.0 (41.0–194.0) 120.0 (41.0–194.0) >0.05
PGA 7.0 (3.0–10.0) 6.0 (3.0–10.0) 6.0 (3.0–10.0) >0.05
Previous hip steroid injection 17.5% 16.7% 20.3% >0.05
Previous hip HA injection 17.5% 17.8% 15.2% >0.05
NSAIDS regular intake 40.0% 42.2% 38.7% >0.05
Analgesics regular intake 63.8% 67.0% 64.5% >0.05
  1. Data are median (range) or percentage of cases. Each WOMAC item was measured on a 11-point Likert scale
  2. ITT: intent-to-treat, PP: per protocol, BMI: body mass index, WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index, PGA: patient global assessment, HA: hyaluronic acid, NSAID: non-steroidal anti-inflammatory drug